New Delhi, March 16 (IANS) A recent study has made significant progress in uncovering the microscopic mechanism behind heavy-ion cancer therapy, which is expected to optimise cancer treatment strategies and promote the development of new radiotherapy technologies.
The findings, led by researchers from the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences and their collaborators, were recently published as a highlighted paper in the journal Physical Review X, Xinhua news agency reported.
Heavy-ion therapy, a cutting-edge radiotherapy technique, uses heavy-ion beams to destroy cancer cells.
Since the concept was proposed in 1946, over 50,000 patients worldwide have undergone heavy-ion treatment.
“Under the same radiation dose, heavy ions exhibit two to three times greater cancer-cell-killing efficiency than traditional X-ray radiotherapy,” said Xu Shenyue, a researcher with the IMP.
Heavy ions can more efficiently cause DNA double-strand breaks in tumour cells, resulting in stronger biological effects.
But the specific microscopic mechanism underlying these effects had long been unclear, Shenyue added.
Researchers conducted experiments at the heavy-ion research facilities in Lanzhou, northwest China’s Gansu Province, to address this question.
For the first time, they observed an intermolecular energy and proton transfer cascade mechanism triggered by heavy-ion irradiation in biomolecular clusters.
“The observed mechanism sheds light on the molecular mechanisms of radiation damage, and may play an essential role in optimising radiotherapy techniques in the future,” said Ma Xinwen, another researcher with the IMP.
The study was conducted by scientists from the IMP, in collaboration with researchers from Russia’s Irkutsk State University, Germany’s Heidelberg University, the University of Science and Technology of China, Xi’an Jiaotong University and Lanzhou University.
Meanwhile, a recent report said that the scientists are working on a new type of antibody that could help fight treatment-resistant breast and ovarian cancers.
The antibody, known as IgE, has shown the ability to stimulate the immune system and slow down tumour growth.
Currently, IgG antibodies are commonly used in immunotherapy to activate the body’s immune system against cancer.
This treatment is often preferred over chemotherapy and radiation because it specifically targets cancer cells.
–IANS
pk/uk
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
